$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter

Brokerages expect that Intrexon Corp (NYSE:XON) will announce sales of $48.79 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Intrexon’s earnings, with the highest sales estimate coming in at $51.91 million and the lowest estimate coming in at $44.65 million. Intrexon reported sales of $46.00 million during the same quarter last year, which would suggest a positive year over year growth rate of 6.1%. The company is scheduled to issue its next earnings report on Wednesday, March 7th.

On average, analysts expect that Intrexon will report full-year sales of $48.79 million for the current year, with estimates ranging from $197.50 million to $206.11 million. For the next year, analysts anticipate that the company will report sales of $249.15 million per share, with estimates ranging from $217.00 million to $281.22 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Intrexon.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%.

A number of research analysts have recently weighed in on the company. Zacks Investment Research raised Intrexon from a “sell” rating to a “hold” rating in a research report on Monday. ValuEngine cut Intrexon from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Northland Securities reaffirmed a “buy” rating and set a $21.00 price objective on shares of Intrexon in a research report on Friday, November 10th. Bank of America lowered their price objective on Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, Stifel Nicolaus lifted their price objective on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $38.50.

In other Intrexon news, CEO Randal J. Kirk purchased 1,000,000 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were bought at an average cost of $12.50 per share, with a total value of $12,500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 56.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC bought a new stake in Intrexon in the 3rd quarter worth approximately $121,000. Tower Research Capital LLC TRC increased its stake in Intrexon by 2,031.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 4,937 shares during the last quarter. SG Americas Securities LLC bought a new stake in Intrexon in the 3rd quarter worth approximately $139,000. Federated Investors Inc. PA bought a new stake in Intrexon in the 2nd quarter worth approximately $172,000. Finally, Quantbot Technologies LP increased its stake in Intrexon by 423.7% in the 3rd quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 8,085 shares during the last quarter. 77.46% of the stock is currently owned by institutional investors.

Intrexon (NYSE XON) traded up $0.66 during mid-day trading on Tuesday, hitting $13.66. The stock had a trading volume of 4,043,900 shares, compared to its average volume of 2,890,414. Intrexon has a 12-month low of $10.26 and a 12-month high of $26.99. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1,660.00, a PE ratio of -12.20 and a beta of 1.33.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/48-79-million-in-sales-expected-for-intrexon-corp-xon-this-quarter.html.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply